Ubs Group Ag Impel Pharmaceuticals Inc Transaction History

Ubs Group Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$0.31 - $1.75 $42 - $239	137 Added 10.47%	1,445 $0
Q1 2023 May 12, 2023	SELL	$0.96 - $4.1 $417 - $1,783	-435 Reduced 24.96%	1,308 $1,000
Q4 2022 Feb 08, 2023	BUY	$2.59 - $4.0 $1,126 - $1,740	435 Added 33.26%	1,743 $6,000
Q2 2022 Aug 10, 2022	SELL	$5.83 - $10.12 $3,789 - $6,577	-650 Reduced 33.2%	1,308 $12,000
Q1 2022 May 16, 2022	SELL	$5.86 - $9.85 $80,334 - $135,033	-13,709 Reduced 87.5%	1,958 $13,000
Q4 2021 Feb 14, 2022	BUY	$8.33 - $12.14 $76,102 - $110,911	9,136 Added 139.89%	15,667 $135,000
Q3 2021 Nov 15, 2021	BUY	$8.38 - $26.13 $44,925 - $140,082	5,361 Added 458.21%	6,531 $80,000
Q2 2021 Aug 13, 2021	BUY	$7.33 - $15.2 $8,576 - $17,784	1,170 New	1,170 $10,000

14.4K

Ticker IMPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,738,800
Market Cap $475K
Description
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The c...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.